![](https://cdn11.bigcommerce.com/s-35tuw7jhw2/product_images/uploaded_images/brand-logos/bioclinic-naturals_278x90.png")
DGL Chewable 180 tabs
- DGL chewable tablets is the form associated with the greatest clinical efficacy, as it allows for licorice to be released in the stomach and dispersed/absorbed by the gastric mucosa*
- Provides 400 mg DGL per tablet, the clinically effective dosage
- Deglycyrrhizination prevents adverse effects associated with licorice consumption*
- Pleasant tasting tablets for better compliance
- Suitable for vegetarians/vegans
DGL by Bioclinic Naturals supports the stomach lining by stimulating mucous formation and secretion, offering almost immediate occasional relief for stomach and digestive tract discomfort. It is specially processed to have glycyrrhizin removed to avoid potential side effects such as elevated blood pressure. The chewable delivery system is preferred because saliva enhances the effect of DGL’s natural compounds.*
Recommendation:
Bioclinic Naturals suggests chewing 1 DGL tablet per day 20 minutes before each meal or as directed by a health care professional.
Serving Size:1 Tablet
Servings Per Container: 180
Amount Per Serving:
Deglycyrrhizinated Licorice 10:1 Extract 400 mg
(Glycyrrhiza glabra) (root) (Providing 4000 mg crude herb licorice)
Other Ingredients: Xylitol, microcrystalline cellulose, aniseed, stearic acid, vegetable grade magnesium stearate (lubricant), silica, Stevia rebaudiana leaf.
Contains no artificial colours, preservatives, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, corn, egg, fish, shellfish, animal products, salt, tree nuts, or GMOs. Suitable for vegetarians/vegans. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.
Consult a health care practitioner if symptoms persist or worsen. Keep out of reach of children.
No known drug interactions. Licorice influences the activity of several cytochrome enzymes, and reduces warfarin activity in animal models, likely due to glycyrrhizic acid activity. Thus DGL use should be carefully monitored in these patients.